Efficacy of recombinant alpha-interferon 2a and 13-cis-retinoic acid in the treatment of squamous cell carcinoma

S. Toma, R. Palumbo, M. Vincenti, E. Aitini, G. Paganini, P. Pronzato, A. Grimaldi, R. Rosso

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Recent in vitro and in vivo studies hypothesize a synergistic effect of 13-cis-Retinoic Acid (13cRA) and recombinant α-IFN 2a (α-IFN) in the treatment of squamous cell carcinoma (SqCC). Patients and methods: 35 patients with SqCC in several sites were treated with 13cRA (0.6-1 mg/kg/day) combined with a-IFN (6 × 106 I.U./day), continuously for 3 months. Results: We observed an objective response in 41% of cases (13/32 evaluable patients) with 5 complete and 8 partial responses. Toxicity was mild and always rapidly reversible, with no haematological side effects. Conclusions: These preliminary data confirm the feasibility and effectiveness of the combination of 13cRA and α-IFN in the therapy of SqCC, also in pre-treated patients, with acceptable toxicity and good compliance.

Original languageEnglish
Pages (from-to)463-465
Number of pages3
JournalAnnals of Oncology
Volume5
Issue number5
Publication statusPublished - May 1994

Keywords

  • 13-cis-retinoic acid
  • Recombinant αIFN 2a
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology
  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Efficacy of recombinant alpha-interferon 2a and 13-cis-retinoic acid in the treatment of squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this